全球临床前影像市场规模（按模式、应用、最终用户、地理和预测）

临床前影像市场规模与预测

2024 年临床前影像市场规模价值为 9.5755 亿美元，预计到 2032 年将达到 14.2772 亿美元，2026 年至 2032 年的复合年增长率为 5.12%。

• 临床前成像是一系列先进的成像技术，用于在人体临床试验之前研究动物模型中的生物过程。这些技术包括 MRI、PET、CT 和生物发光成像，使研究人员能够研究新药的效果、追踪疾病发展并评估体内治疗反应。临床前影像在药物发现和开发中至关重要，因为它使科学家能够收集有关新疗法疗效和安全性的关键数据、研究药物动力学并改进测试设计。
• 随着人工智慧和机器学习的融入，临床前成像领域即将迎来重大突破，影像处理和解读也将得到改进。成像技术的进步有望提高灵敏度和分辨率，从而能够在分子层面上更准确地评估生物过程。
• 对个体化医疗的日益关注可能会推动定製成像技术的发展，这种技术可以预测个体对药物的反应，最终改善转化研究成果并加快人体临床试验的进程。

全球临床前影像市场动态

影响全球临床前影像市场的关键市场动态是：

关键市场驱动因素

• 增加药物研发投入：据美国国立卫生研究院 (NIH) 称，製药公司将在 2023 年投资 950 亿美元用于研发，比 2020 年增长 32%。 FDA 预测，2021 年至 2023 年间，需要临床前影像的临床实验新药申请将增加 45%。这种激增是由对更准确、更详细的治疗效果和安全性数据的需求所驱动，正如 PhRMA 的调查结果显示，目前 78% 的药物开发项目使用先进的临床前成像，高于 2020 年的 52%。这种成长凸显了影像在加快药物开发、改进测试设计和提高成功率方面发挥的关键作用。
• 慢性病的流行：慢性病的增加推动了对更优临床前研究工具的需求。世界卫生组织 (WHO) 预计到 2040 年癌症患者数量将增加 60%；美国疾病管制与预防中心 (CDC) 则表示，每 10 个美国人中就有 6 人至少患有一种慢性病。这一增长得益于早期检测、精准疾病建模和治疗方法研发的进步。美国国家癌症实验室 (美国 National Cancer Lab) 宣布，临床前影像的资金将增加 89%，到 2023 年将达到 28 亿美元，这凸显了影像在解决这些日益严重的健康问题中的关键作用。
• 成像模式的技术进步：成像模式的技术进步显着提升了临床前造影成像的能力，从而提高了其在研究中的利用率。医学影像与技术联盟估计，2021年至2023年间，影像系统的准确度将提高156%，而多模态方法的准确度将提高234%，从而实现更全面的资料收集。 《核子医学杂誌》报告称，2023年，人工智慧辅助影像将使研究时间缩短42%，准确度提高68%。

主要问题

• 影像系统高成本：MRI、PET 和 CT 等先进的临床前成像技术的购买和维护成本高。这些系统高达数百万美元，小型研究机构难以负担，限制了广泛应用。高昂的成本增加了整体研究成本，并影响了製药公司的研发预算。这项挑战，尤其是在新兴市场，加剧了人们的负担能力，并阻碍了市场扩张。
• 资料管理与储存问题：临床前影像会产生大量数据，必须妥善储存、处理和分析。许多研究机构缺乏管理大型资料集所需的基础设施和技能，导致资料处理和分析效率低。不良的资料管理会降低研究品质、延误计划、增加营运成本，并且是市场拓展的主要障碍，尤其是在影像技术不断进步的今天。
• 漫长的开发和商业化週期：开发新的临床前成像技术并将其推向市场需要大量的研究、开发和监管核准流程。缓慢的发明和商业化速度可能会减缓新成像技术的普及，并限制市场成长。如此漫长的周期也会阻碍投资，尤其是对规模较小的公司而言，因为投资回报可能需要数年时间才能实现，进而影响市场动态。

主要趋势

• 多模态成像技术的应用日益广泛：结合多种显像模式（例如MRI、PET和CT）的多多模态成像技术的应用日益广泛，使得在临床前研究中能够全面研究生物过程成为可能。这一趋势有助于更全面、更全面地了解疾病发展和治疗效果，从而提高数据品质。人们对这些整合技术的需求日益增长，因为它们能够在单次实验中收集到更可靠、更多样化的数据，从而提高研究效率。
• 向非侵入性成像方法的转变：非侵入性成像技术因其能够在不损害动物模型的情况下追踪疾病进展而日益普及。光学成像和核磁共振成像等技术可以进行长期反覆观察，为研究人员提供宝贵的纵向数据。这种向非侵入性技术的转变推动了对先进的临床前成像技术的需求，这些技术既能减少伦理担忧，又能提高实验数据的品质。
• 分子影像技术的发展：分子影像技术能够洞察细胞和分子过程，在临床前研究中的重要性日益凸显。它使研究人员能够在分子层面上研究疾病通路，从而实现更早的诊断和更精准的标靶治疗。随着个人化医疗的加速发展，分子影像技术在标靶药物研发中发挥关键作用，因此其在临床前研究中的应用日益广泛，推动了市场的成长。

目录

第 1 章全球临床前影像市场简介

• 市场概览
• 研究范围
• 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

• 资料探勘
• 验证
• 第一手资料
• 资料来源列表

第四章全球临床前影像市场展望

• 概述
• 市场动态
  • 驱动程式
  • 限制因素
  • 机会

5. 全球临床前影像市场（按模式）

• 概述
• 磁振造影
• 电脑断层扫描
• 正电子CT
• 单光子发射电脑断层扫描
• 光学成像
• 超音波成像

6. 全球临床前影像市场（按应用）

• 概述
• 肿瘤学
• 神经病学
• 心臟病学
• 发炎
• 感染疾病
• 代谢疾病

7. 全球临床前影像市场（按最终用户）

• 概述
• 製药和生物技术公司
• 合约研究组织
• 研究机构和学术中心
• 医院诊所

8. 全球临床前影像市场（按地区）

• 概述
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 其他的
  • 拉丁美洲
  • 中东和非洲

9. 全球临床前影像市场的竞争格局

• 概述
• 各公司市场排名
• 重点发展策略

第十章 公司简介

• Bruker Corporation
• Siemens AG
• General Electric
• TriFoil Imaging
• PerkinElmer, Inc.
• VisualSonics Inc.（Fujifilm）
• Mediso Ltd.
• Agilent Technologies
• MILabs BV
• MR Solutions

第十一章 重大进展

• 产品发布/开发
• 合併与收购
• 业务扩展
• 伙伴关係与合作

第十二章 附录

• 相关调查

Preclinical Imaging Market Size And Forecast

Preclinical Imaging Market size was valued at USD 957.55 Million in 2024 and is projected to reach USD 1427.72 Million by 2032, growing at a CAGR of 5.12% from 2026 to 2032.

• Preclinical imaging is a collection of advanced imaging techniques used to examine biological processes in animal models before human clinical trials. These techniques, which include MRI, PET, CT, and bioluminescence imaging, enable researchers to study the effects of novel medications, follow disease development, and assess therapy responses in vivo. Preclinical imaging is important in drug discovery and development because it allows scientists to collect key data on the efficacy and safety of new treatments, as well as examine pharmacokinetics and improve study designs.
• Preclinical imaging is poised for substantial breakthroughs with the incorporation of artificial intelligence and machine learning to improve picture processing and interpretation. As imaging technologies advance, we should expect increased sensitivity and resolution, allowing for more exact assessments of biological processes at the molecular level.
• The increased emphasis on customized medicine is likely to stimulate the development of tailored imaging techniques capable of predicting individual responses to medicines, ultimately enhancing translational research outcomes and expediting the journey to human clinical trials.

Global Preclinical Imaging Market Dynamics

The key market dynamics that are shaping the global preclinical imaging market include:

Key Market Drivers:

• Rising Investment in Pharmaceutical R&D: Rising investment in pharmaceutical R&D is fueling robust growth in the preclinical imaging market, with pharmaceutical companies investing USD 95 Billion in R&D in 2023, up 32% from 2020, according to the NIH. The FDA also forecasts a 45% increase in investigational new medication applications that need preclinical imaging between 2021 and 2023. This spike is being driven by the demand for more precise, in-depth data on therapeutic efficacy and safety, as indicated by PhRMA's findings that 78% of drug development programs currently use advanced preclinical imaging, up from 52% in 2020. This growth underlines imaging's critical role in expediting drug development, refining study designs, and increasing success rates.
• Growing Prevalence of Chronic Diseases: The increasing frequency of chronic diseases is driving the need for better preclinical research tools. Cancer cases are expected to climb by 60% by 2040, according to the WHO, and 6 out of 10 Americans already have at least one chronic ailment, according to the CDC, resulting in a 67% increase in preclinical research since 2021. This increase is motivated by the need for early identification, precise disease modeling, and improved treatment development. The National Cancer Institute's 89% increase in funding for preclinical imaging, totaling $2.8 billion in 2023, emphasizes the critical significance of imaging in addressing these growing health concerns.
• Technological Advancements in Imaging Modalities: Technological advancements in imaging modalities are greatly improving the capabilities of preclinical imaging, resulting in its increased use in research. The Medical Imaging and Technology Alliance estimated that imaging system precision improved by 156% between 2021 and 2023, while multimodal approaches increased by 234%, allowing for more comprehensive data collection, according to the European Society of Molecular Imaging. According to the Journal of Nuclear Medicine, AI-enhanced imaging will decrease research durations by 42% and improve accuracy by 68% in 2023.

Key Challenges:

• High Cost of Imaging Systems: Advanced preclinical imaging technologies, including as MRI, PET, and CT, are expensive to purchase and maintain. These systems can cost millions of dollars, making them unavailable to smaller research institutes and limiting their broad use. The high costs increase overall research expenses, hurting pharmaceutical companies' R&D budgets. This challenge stifles market expansion since affordability becomes a hurdle, particularly in emerging markets.
• Data Management and Storage Issues: Preclinical imaging produces a large amount of data, which must be appropriately saved, handled, and analyzed. Many institutions lack the necessary infrastructure and skills to manage massive datasets, resulting in inefficiencies in data processing and analysis. Poor data management can jeopardize research quality, delay projects, and raise operational expenses, posing a substantial impediment to market expansion, especially as imaging technologies advance.
• Long Development and Commercialization Cycles: Creating new preclinical imaging technologies and bringing them to market requires extensive research, development, and regulatory approval processes. The slow rate of invention and commercialization might cause delays in the adoption of new imaging technologies, limiting market growth. This protracted cycle also discourages investment, particularly from smaller enterprises, because the return on investment might take years to realize, influencing market dynamics.

Key Trends:

• Increasing Use of Multimodal Imaging Techniques: The increasing use of multimodal imaging techniques, which combine several imaging modalities such as MRI, PET, and CT, allows for complete investigation of biological processes in preclinical studies. This trend improves data quality by providing a more complete and comprehensive understanding of illness development and treatment efficacy. The capacity to collect more robust and diversified data in a single experiment is boosting demand for these integrated technologies, which increase research efficiency.
• Shift to Non-invasive Imaging Methods: Non-invasive imaging techniques are gaining popularity due to their ability to track disease progression without causing harm to the animal model. Methods such as optical imaging and MRI allow for repeated observations throughout time, giving researchers valuable longitudinal data. This shift toward non-invasive techniques is increasing demand for sophisticated preclinical imaging technologies, which lessen ethical issues while also improving experimental data quality.
• Growth in Molecular Imaging: Molecular imaging, which allows for the viewing of cellular and molecular processes, is becoming more important in preclinical research. It enables researchers to investigate disease pathways at the molecular level, resulting in earlier identification and more precise treatment targeting. As personalized medicine gains pace, molecular imaging plays an important role in creating targeted medicines, increasing usage in preclinical investigations, and propelling market growth.

Global Preclinical Imaging Market Regional Analysis

Here is a more detailed regional analysis of the global preclinical imaging market:

North America:

• North America's dominance in the preclinical imaging market is primarily due to its strong pharmaceutical and biotechnology sectors. The United States accounts for about half of the global market, owing to considerable investments in research and infrastructure. As of 2023, the National Institutes of Health (NIH) reported a 156% growth in preclinical imaging spending, totaling USD 12.7 Billion. This expansion is being driven by an increasing need for improved imaging technologies in drug discovery and development, notably with the rise of customized medicine.
• Pharmaceutical companies have increasingly utilized preclinical imaging, with the United States Food and Drug Administration (FDA) reporting an 89% increase in companies adopting these technologies between 2021 and 2023. Canada's biotechnology sector also contributes, with preclinical imaging expenditures increasing by 178%, reinforcing North America's leading spot.
• Investment in research and development (R&D) is critical to boosting North America's preclinical imaging market. The National Science Foundation reports that between 2020 and 2023, private-sector R&D spending on imaging increased by 234%, reaching USD 18.5 Billion. This is supplemented by a predicted 67% increase in federal funding for preclinical research by 2026. Technological developments have also been important drivers, with institutions purchasing 45% more preclinical imaging equipment in 2023 compared to 2021. Such infrastructure expansion has resulted in speedier drug development schedules, with the FDA reporting a 145% increase in medication applications that include preclinical imaging data. This incorporation of imaging technology into drug discovery speeds up the research process and increases success rates, consolidating North America's market leadership.

Asia Pacific:

• The Asia Pacific region is experiencing tremendous expansion in the preclinical imaging market, making it the fastest-growing market globally. Between 2021 and 2023, the market grew by 189% to USD 5.8 Billion, owing to increased investments in healthcare infrastructure and technology improvements. China, Japan, and India have greatly increased funding for preclinical research. China's investment alone increased by 234% to ¥45.6 billion (USD 7.1 Billion) during this period. Government initiatives, such as public-private partnerships and collaborations between academic institutions and pharmaceutical businesses, have also increased, adding to market growth. The expansion of preclinical imaging facilities in South Korea and Australia demonstrates the region's growing commitment to complex research capabilities, establishing Asia Pacific as a focus for medical imaging innovation.
• Population growth and increased healthcare spending are also propelling Asia Pacific's preclinical imaging market. As the middle class grows and discretionary income improves, healthcare spending in the region climbed by 89% between 2021 and 2023. The World Bank anticipates that by 2025, 45% of the region's population will have access to advanced healthcare services, greatly increasing demand for breakthrough medical technology such as preclinical imaging. Rising research efforts and government-sponsored collaborations are creating a favorable atmosphere for preclinical imaging improvements, hastening expansion in the region.

Global Preclinical Imaging Market: Segmentation Analysis

The Global Preclinical Imaging Market is Segmented on the basis of Modality, Application, End-User, And Geography.

Preclinical Imaging Market, By Modality

• Magnetic Resonance Imaging
• Computed Tomography
• Optical Imaging
• Ultrasound Imaging

Based on Modality, the market is bifurcated into Magnetic Resonance Imaging, Computed Tomography, Optical Imaging, and Ultrasound Imaging. Magnetic Resonance Imaging (MRI) leads the preclinical imaging market due to its high resolution and non-invasive nature, making it perfect for precise anatomical and functional analyses. The broad use of MRI in neurological and cancer research has cemented its position as the leading technology. Optical Imaging is the fastest expanding segment, thanks to its capacity to deliver real-time molecular imaging with little invasiveness. Its rapid expansion is being driven by increased demand in oncology and cardiovascular research, where early-stage drug discovery necessitates sensitive, real-time imaging of biologic processes.

Preclinical Imaging Market, By Application

• Research and Development
• Drug Discovery

Based on Application, the market is segmented into Research and Development and Drug Discovery. Drug discovery is the dominant segment in the preclinical imaging market due to its critical role in determining medication efficacy and safety prior to clinical testing. Drug discovery is the most important application because to rising demand for precision medicine and increased pharmaceutical R&D investments. The fastest-growing category is research and development (R&D), which is driven by increased investment in breakthrough technologies and the need for enhanced imaging techniques to hasten the discovery of new medicines, notably in oncology and neurological disorders.

Preclinical Imaging Market, By End-User

• Pharmaceutical and Biotechnology Companies
• Research Institutes

Based on End-User, the market is segmented into Pharmaceutical and Biotechnology Companies and Research Institutes. Pharmaceuticals and Biotechnology Companies dominate the preclinical imaging market because they make substantial use of imaging technologies in drug development and testing. Their enormous investments in R&D, along with the quest for speedier drug discovery methods, position them as the market leader. Research institutes are the fastest-growing segment, owing to increased government financing and academic-industry cooperation. These institutes are quickly using advanced imaging technologies to support cutting-edge research, including disease models and therapeutic development.

Preclinical Imaging Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World
• On the basis of Geography, the Global Preclinical Imaging Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. North America dominates the preclinical imaging market thanks to its strong pharmaceutical and biotechnology industries, superior infrastructure, and large R&D investments. The Asia Pacific region is witnessing the quickest growth, owing to rising healthcare spending, increased research activity, and increased awareness of preclinical imaging techniques.

Key Players

The "Global Preclinical Imaging Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Bruker Corporation, Siemens A.G., General Electric, TriFoil Imaging, PerkinElmer, Inc., VisualSonics, Inc., Mediso Ltd., Agilent Technologies, MILabs B.V., MR Solutions, and Molecube. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Preclinical Imaging Market Recent Developments
• In April 2024, Spectral Instruments Imaging announced the release of Aura 4.5, the most recent version of its in vivo imaging software.
• In April 2023, Southern Scientific announced that it will become the new UK distributor for Spectral Instruments Imaging, a leading provider of preclinical in vivo imaging equipment.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL PRECLINICAL IMAGING MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL PRECLINICAL IMAGING MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities

5 GLOBAL PRECLINICAL IMAGING MARKET, BY MODALITY

• 5.1 Overview
• 5.2 Magnetic Resonance Imaging
• 5.3 Computed Tomography
• 5.4 Positron Emission Tomography
• 5.5 Single Photon Emission Computed Tomography
• 5.6 Optical Imaging
• 5.7 Ultrasound Imaging

6 GLOBAL PRECLINICAL IMAGING MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Oncology
• 6.3 Neurology
• 6.4 Cardiology
• 6.5 Inflammation
• 6.6 Infectious Diseases
• 6.7 Metabolic Diseases

7 GLOBAL PRECLINICAL IMAGING MARKET, BY END-USERS

• 7.1 Overview
• 7.2 Pharmaceutical & Biotechnology Companies
• 7.3 Contract Research Organizations
• 7.4 Research Institutions & Academic Centers
• 7.5 Hospitals & Clinics

8 GLOBAL PRECLINICAL IMAGING MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East & Africa

9 GLOBAL PRECLINICAL IMAGING MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Bruker Corporation
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Siemens A.G.
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 General Electric
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 TriFoil Imaging
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 PerkinElmer, Inc.
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 VisualSonics Inc. (Fujifilm)
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Mediso Ltd.
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Agilent Technologies
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 MILabs B.V.
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 MR Solutions
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 KEY DEVELOPMENTS

• 11.1 Product Launches/Developments
• 11.2 Mergers and Acquisitions
• 11.3 Business Expansions
• 11.4 Partnerships and Collaborations

12 APPENDIX

• 12.1 Related Research